• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Introduction to (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine (CAS No. 1332608-95-3)

(1,4-Dimethyl-1H-pyrazol-3-yl)methanamine is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by its CAS number 1332608-95-3, has garnered attention due to its potential applications in drug discovery and development. The molecular structure of this compound includes a pyrazole ring substituted with two methyl groups at the 1 and 4 positions, and an amine group at the 3 position, which contributes to its distinct chemical behavior and reactivity.

The pyrazole core is a heterocyclic aromatic compound that is widely recognized for its biological activity. Pyrazole derivatives have been extensively studied for their role in various pharmacological applications, including antiviral, anti-inflammatory, and anticancer agents. The presence of methyl groups at the 1 and 4 positions enhances the lipophilicity of the molecule, making it more soluble in organic solvents and potentially improving its bioavailability when administered orally or topically.

The amine group at the 3 position of the pyrazole ring introduces basicity to the molecule, which can be exploited in various chemical reactions such as nucleophilic substitution or condensation reactions. This feature makes (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine a versatile intermediate in synthetic chemistry, particularly in the preparation of more complex molecules with tailored biological activities.

Recent research has highlighted the potential of pyrazole derivatives as scaffolds for developing novel therapeutic agents. For instance, studies have demonstrated that certain pyrazole-based compounds exhibit inhibitory effects on enzymes involved in inflammatory pathways, making them promising candidates for treating chronic inflammatory diseases. Additionally, modifications of the pyrazole ring have been explored to enhance binding affinity to target proteins, which is crucial for developing more effective drugs.

In the context of drug development, (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine has been investigated for its potential role as a precursor in synthesizing more complex pharmacophores. The compound's ability to undergo various chemical transformations allows researchers to modify its structure systematically, enabling the exploration of different biological activities. This flexibility is particularly valuable in medicinal chemistry, where iterative design and optimization are essential for identifying lead compounds with desired therapeutic properties.

The synthesis of (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine involves multi-step organic reactions that require careful control of reaction conditions to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriate precursors followed by functional group transformations. Advances in synthetic methodologies have enabled more efficient and scalable production of this compound, facilitating its use in both academic research and industrial applications.

The biological activity of (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine has been explored through various in vitro and in vivo studies. Preliminary findings suggest that this compound may exhibit interactions with biological targets relevant to neurological disorders, cancer, and infectious diseases. These interactions are being further investigated to understand the mechanisms of action and potential therapeutic benefits. The compound's unique structural features make it a valuable tool for studying enzyme inhibition and receptor binding interactions.

In conclusion, (1,4-Dimethyl-1H-pyrazol-3-yl)methanamine (CAS No. 1332608-95-3) is a compound of considerable interest in pharmaceutical research due to its structural complexity and potential biological activities. Its role as an intermediate in synthetic chemistry and a precursor for developing novel therapeutic agents underscores its importance in drug discovery efforts. Continued investigation into this compound is expected to yield new insights into its pharmacological properties and applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)